Awards and Funding

AWARDS

  • 2024- Notre Dame Integrated Imaging Facility Award for Best Imaging Publication to Kevin Armknecht of Nallathamby lab  (Nanoscale Advances, 2024, 6, 1145-1162).
  • 2024- Nanoscale Advances, 2024, 6, 1145-1162 included in the 2024 Popular Advances collection (including articles which have been very well received by the community).
  • 2023- 1st Prize for poster in “Antimicrobial Countermeasures for Wound Infections in Military Personnel” at the 2023 Military Health System Research Symposium in Orlando, FL
  • 2016-  $1000 for prototype submission to the InnoCentive Challenge “Minimally Invasive Skin Biopsy Technique for Gene  Expression Measurement” (ID 9933669)
  • 2016- 5th Annual Harper Research Day Poster Competition prize from the Mike and Josie Harper Cancer Research Institute
  • 2015- Pfizer Young Investigator Poster Award for the work on “Modular Assembly of Surface Functionalized Core-Shell  Nanoparticles as Novel Image Contrast Agents”
  • 2015- $3000 InnoCentive Challenge Prize for solving “Incorporating Drugs into an Exosome” (ID 9933675)

CURRENT FEDERAL AND FOUNDATION FUNDING

  • 2026 – 2029 Evaluation of Novel Antibacterial Nanoparticle Therapeutics for the Treatment of Combat-Relevant Pathogens in vitro and Pre-Clinical Animal Models, DHA MID (Invited), $295,000; 1 month Co-PI effort +  12 months graduate student; SCORE: 1.3–1.5 (Outstanding); Resubmitted October 16, 2024; Co-PI. (Funded Army Acquisitions Contract negotiation in progress) Expected Start Date in May 2026
  • 2025 – 2027 Multispecific Bridge Nanoparticles to Engage T Cells and Off-the-Shelf CAR-T Cells Against Antigen(+) EC Tumors to Enhance Antitumor Immune Activity, CDMRP-PRCRP IDEA award (Invited) HT94252510332, $694,330; 1.5 months effort, PI; Collaboration with IUSM-SB.

Externally Funded Projects Completed (Previous years):

  • 2023 – 2024 AFM study to Elucidate Mechano-Electrical Differences in Cell Membranes of Cancer Cells and Normal Primary Cells using Magnetoelectric Nanoparticles, DOE-CNMS2022-B-01661, $0 (user facility access for instrument and CNMS PI time); PI: P.D. Nallathamby/L. Collins.
  • 2022 – 2024 Off-the-Shelf CAR-T (uCAR-T) Cell Re-targeted to Multiple Cancer Types using Dual-Antibody, Bridge Nanoparticles and Controllable uCART Activation, CTSI-Think Tank/IU-B, $10,000; 0.05 months effort, PI; Milestone I met, applying for Phase II in vivo studies.
  • 2021– 2022 Aptima /Sentinel/ND/Purdue “SMARTWATCH: Sensor-based Monitoring and Assessment via Remote Telemetry and Wearables for Augmentation of Tactical Care and Health”, NBMC-AFRL, $1,384,355.19; 4.2% FTE as senior personnel.
  • 2020– 2021 P.D. Nallathamby, S. Zhang, F. Liu “Neutralizing the Cardiotoxicity of Anthracyclines”, American Cancer Society- Institutional Research Grant, $32,450, in vivo experiments.
  • 2018- 2021 P.D. Nallathamby, S. Zhang, P. Helquist “Magnetic Nanocarrier-based, Precise Chemotherapeutic Delivery to Metastatic Cancer Cells In Vivo“, American Cancer Society- Institutional Research Grant, $30,000, in vivo experiments and 8% FTE.
  • 2019 – 2020 P.D. Nallathamby, S.W. Lee, J. Hopf “Biomimetic Infection Reporting Antimicrobial Nanoparticles for Wound and Surgical Site Applications”, Clinical Translational Sciences Institute-Project Development Team, $20,000 in vitro/ in vivo supplies and 25% stipend post-doctoral salary.